fcov
biotyp
caus
fip
design
felin
infecti
periton
viru
fipv
distinguish
abil
infect
macrophag
monocyt
antigen
similar
virul
counterpart
fcov
biotyp
design
felin
enter
coronaviru
fecv
usual
caus
mild
enter
unabl
effici
infect
macrophag
monocyt
fcov
spike
protein
mediat
viral
entri
host
cell
previous
shown
determin
distinct
tropism
exhibit
certain
isol
fipv
fecv
howev
molecular
mechan
underli
viral
pathogenesi
yet
determin
show
fecv
strain
wsu
highli
depend
host
cell
cathepsin
b
cathepsin
l
activ
entri
host
cell
well
low
ph
endocyt
compart
addit
cathepsin
b
cathepsin
l
abl
induc
specif
cleavag
event
spike
protein
contrast
host
cell
entri
fipv
strain
wsu
proce
independ
cathepsin
l
activ
low
ph
still
highli
depend
cathepsin
b
activ
case
infect
primari
felin
monocyt
also
depend
host
cell
cathepsin
b
activ
indic
host
cell
cathepsin
may
play
role
distinct
tropism
display
differ
felin
coronaviru
biotyp
coronavirus
envelop
positivestrand
rna
virus
replic
cytoplasm
lai
holm
perlman
et
al
distinct
set
clubshap
spike
envelop
wwwelseviercomlocatevetm
avail
onlin
wwwsciencedirectcom
veterinari
microbiolog
compris
viral
spike
protein
coronaviru
protein
primari
determin
cell
tropism
pathogenesi
respons
appar
suffici
receptor
bind
fusion
gallagh
buchmeier
overal
coronaviru
protein
categor
class
fusion
protein
earp
et
al
base
presenc
characterist
heptad
repeat
bosch
et
al
chamber
et
al
kliger
levanon
show
characterist
featur
fusion
protein
influenza
viru
ha
retrovirus
env
paramyxovirus
f
extens
character
structur
biophys
level
colman
lawrenc
mani
viral
fusion
protein
known
activ
follow
cleavag
host
cell
proteas
klenk
garten
extens
document
orthomyxoand
paramyxovirus
case
high
pathogen
avian
influenza
strain
mutat
region
cleavag
site
modifi
trypsinlik
monobas
furinlik
polybas
cleavag
site
allow
system
spread
within
host
henc
show
drastic
increas
virul
klenk
et
al
although
coronavirus
show
structur
similar
canon
class
fusion
protein
appear
signific
differ
regard
role
proteolyt
cleavag
fusion
activ
bosch
rottier
coronaviru
protein
consist
two
princip
domain
respons
receptor
bind
mediat
membran
fusion
group
coronavirus
eg
infecti
bronchiti
viru
ibv
ubiquit
cleavag
precursor
protein
form
subunit
cavanagh
et
al
cleavag
appar
carri
furin
group
virus
eg
mous
hepat
viru
mhv
cleavag
variabl
frana
et
al
abil
cleav
boundari
studi
quit
extens
wentworth
holm
correl
cleavag
increas
cellcel
fusion
gener
appear
direct
link
syncytia
format
analog
protein
cleavag
pathogen
hingley
et
al
group
protein
remain
uncleav
viru
particl
qiu
et
al
group
virus
eg
human
coronaviru
felin
coronaviru
fcov
cleavag
consid
occur
vennema
et
al
howev
recent
identif
group
coronaviru
furinlik
motif
pratelli
et
al
suggest
may
case
group
member
infect
cell
sever
coronavirus
shown
sensit
presenc
lysosomotrop
agent
nh
cl
rais
ph
endosom
blau
holm
gallagh
et
al
hansen
et
al
cavanagh
mizzen
et
al
data
suggest
phdepend
rout
coronaviru
entri
endosom
case
eg
ibvand
coronaviru
fusion
reaction
clearli
shown
trigger
low
ph
chu
et
al
eifart
et
al
wherea
case
eg
sarscov
suggest
low
ph
endosom
import
activ
cathepsin
proteas
prime
fusion
event
simmon
et
al
fusion
activ
consid
phindepend
classic
cathepsin
cystein
proteas
typic
present
within
endosomelysosom
system
host
cell
barrett
et
al
role
cathepsin
entri
nonenvelop
reovirus
known
time
ebert
et
al
golden
et
al
recent
becom
appar
fusion
protein
sever
famili
envelop
virus
cleav
proteas
exampl
recent
identifi
paramyxovirus
hendra
nipah
diederich
et
al
pager
et
al
pager
dutch
well
ebola
viru
chandran
et
al
sanchez
schornberg
et
al
moloney
murin
leukemia
viru
kumar
et
al
case
coronavirus
sarscov
thought
requir
cathepsin
activ
huang
et
al
qiu
et
al
simmon
et
al
simmon
et
al
cathepsin
l
predominantli
involv
sarscov
entri
cathepsin
b
mediat
cleavag
viru
entri
sarscov
neither
site
cathepsin
lmediat
proteolysi
cleav
product
produc
known
although
cathepsin
b
may
cleav
junction
qiu
et
al
coronavirus
ibv
consid
depend
cathepsin
chu
et
al
huang
et
al
qiu
et
al
felin
infecti
periton
fip
highli
lethal
system
infect
cat
caus
group
felin
coronaviru
fcov
fipv
biotyp
haijema
et
al
olsen
howev
normal
circumst
fcov
caus
mild
often
inappar
enter
case
viru
classifi
felin
enter
coronaviru
fecv
biotyp
de
grootmijn
et
al
haijema
et
al
fcov
exist
either
serotyp
less
commonli
serotyp
ii
case
spike
protein
share
extens
similar
canin
coronaviru
ccov
transmiss
gastroenter
viru
tgev
due
rel
eas
growth
cell
cultur
serotyp
ii
fcov
subject
degre
molecular
character
particular
two
strain
serotyp
ii
fcov
wsu
wsu
serv
model
virus
caus
either
mild
enter
fip
respect
pedersen
et
al
b
virus
thu
refer
intern
mutat
model
fip
believ
process
mutat
within
individu
cat
confer
abil
fecv
infect
macrophag
monocyt
allow
system
spread
becom
viru
caus
fip
vennema
et
al
despit
extens
studi
genom
differ
determin
whether
fcov
behav
fecv
fipv
still
larg
unknown
haijema
et
al
howev
case
serotyp
ii
fcov
map
studi
spike
protein
determin
critic
domain
involv
switch
fipv
surprisingli
domain
receptorbind
domain
import
critic
region
map
ctermin
part
fusion
domain
light
recent
determin
involv
cathepsin
activ
coronaviru
protein
reason
fcov
spike
protein
might
target
cathepsin
viru
entri
might
explain
unusu
pathogen
properti
fipv
examin
entri
pathway
felin
coronavirus
show
differenti
role
low
ph
spike
protein
cleavag
cathepsin
b
cathepsin
l
crandellre
felin
kidney
crfk
cell
felin
fetal
lung
cell
akd
obtain
american
type
cultur
collect
atcc
cell
provid
dr
colin
parrish
cornel
univers
baker
institut
anim
health
cell
provid
dr
ed
dubovi
anim
health
diagnost
center
new
york
state
colleg
veterinari
medicin
cornel
univers
primari
felin
monocyt
individu
purifi
blood
three
spf
cat
liberti
research
inc
waverli
ny
use
standard
ficollpaqu
gradient
ge
healthcar
specifi
manufactur
monocyt
seed
plate
allow
attach
culturetr
glass
coverslip
overnight
wash
puriti
monocyt
prepar
check
immunofluoresc
microscopi
use
monocyt
marker
crfk
akd
cell
grown
presenc
co
media
ph
supplement
fetal
bovin
serum
fb
mm
glutamin
uml
penicillin
mgml
streptomycin
monocyt
cultur
condit
except
media
supplement
fb
fipv
wsu
obtain
atcc
fecv
wsu
provid
dr
ed
dubovi
anim
health
diagnost
center
new
york
state
colleg
veterinari
medicin
cornel
univers
grown
cell
grown
crfk
cell
supernat
collect
cpe
observ
cell
supernat
clarifi
low
speed
centrifug
step
g
min
viral
particl
pellet
centrifug
rpm
rotor
sorval
min
pellet
resuspend
either
phosphatebuff
salin
ph
infect
assay
acet
buffer
ph
cathepsin
cleavag
assay
viru
titer
determin
tcid
assay
crfk
cell
use
standard
techniqu
gray
antifcov
nucleocapsid
olsen
et
al
cystein
proteas
inhibitor
ethyl
ester
loxistatin
cathepsin
b
inhibitor
propylcarbamoyl
lisoleucyllprolin
methyl
ester
cathepsin
k
inhibitor
nbenzyloxycarbonylleucyl
nbocphenylalanylleucyl
carbohydrazid
bocl
bafilomycin
purchas
calbiochem
san
diego
ca
cathepsin
l
inhibitor
zphetyr
tbu
diazomethylketon
zfi
tbu
dmk
purchas
axxora
san
diego
ca
growth
assay
cell
seed
confluenc
tissu
culturetr
plate
cell
preincub
specifi
treatment
serumfre
media
min
addit
viru
final
concentr
tcid
ml
h
cell
wash
media
replac
fresh
serumfre
media
h
supernat
collect
frozen
later
determin
viral
titer
tcid
assay
infect
assay
cell
seed
confluenc
plate
tissu
culturetr
glass
coverslip
cell
treat
inhibitor
specifi
either
min
min
addit
viru
viru
ad
final
concentr
tcid
ml
infect
control
cell
condit
test
h
postinfect
cell
fix
paraformaldehyd
stain
antifcov
nucleocapsid
mab
essenti
describ
previous
chu
et
al
influenza
viru
sendai
viru
infect
assay
perform
previous
describ
chu
et
al
assay
repeat
least
three
time
widefield
imag
captur
quantifi
per
experiment
replic
cell
view
nikon
eclips
fluoresc
microscop
imag
captur
sensicam
em
camera
iplab
softwar
transfer
imagej
softwar
http
rsbinfonihgovij
determin
infect
frequenc
concentr
viral
particl
tcid
ml
suspend
acet
buffer
ph
ml
viru
prepar
incub
either
purifi
cathepsin
l
calbiochem
san
diego
ca
purifi
cathepsin
b
calbiochem
san
diego
ca
final
concentr
mm
h
follow
addit
u
pngase
f
new
england
biolab
ipswich
allow
differenti
multipli
glycosyl
speci
sd
sampl
buffer
ad
reaction
heat
separ
use
sdspage
gel
v
h
gel
electroblot
pvdf
membran
block
bovin
serum
albumin
probe
antifcov
spike
protein
mab
membran
develop
use
antimous
antibodi
link
horseradish
peroxidas
southernbiotech
birmingham
al
ecl
substrat
pierc
rockford
il
imag
captur
use
fujifilm
ccd
camera
western
blot
densitometri
analysi
spike
protein
cleavag
perform
use
imagej
softwar
percent
cleavag
determin
divid
pixel
intens
cleav
spike
protein
band
total
pixel
intens
cleav
uncleav
spike
protein
band
combin
determin
role
cystein
proteas
life
cycl
first
pretreat
cell
cellperm
irrevers
cystein
proteas
inhibitor
nonselect
inhibit
rang
cystein
proteas
cell
infect
either
control
cell
infect
influenza
viru
believ
requir
proteolyt
activ
cystein
proteas
entri
collect
cell
supernat
h
postinfect
assay
viru
product
tcid
assay
pretreat
significantli
reduc
product
viral
particl
compar
control
cell
pretreat
dmso
alon
fig
expect
effect
influenza
viru
infect
investig
potenti
role
cathepsin
growth
cell
pretreat
specif
inhibitor
cathepsin
b
cathepsin
l
zfi
tbu
dmk
cathepsin
k
shown
fig
cathepsin
b
inhibitor
consider
limit
product
contrast
cathepsin
l
inhibitor
neglig
effect
howev
greatli
diminish
propag
cathepsin
k
inhibitor
signific
effect
either
viru
fig
specif
cathepsin
inhibitor
also
effect
influenza
viru
infect
data
indic
requir
cathepsin
b
activ
propag
wherea
select
requir
cathepsin
l
activ
establish
effect
cathepsin
b
l
inhibitor
occur
viru
entri
cell
treat
five
log
dilut
inhibitor
either
min
preinfect
min
postinfect
infect
cell
fix
h
postinfect
infect
cell
detect
immunofluoresc
microscopi
use
antifcov
nucleocapsid
monoclon
antibodi
quantifi
fig
preincub
specif
cathepsin
b
inhibitor
almost
complet
block
infect
howev
treatment
entri
effect
fig
consist
data
viral
growth
assay
cathepsin
l
inhibitor
effect
entri
except
limit
effect
highest
concentr
test
fig
preincub
either
cathepsin
b
cathepsin
l
inhibitor
potent
block
infect
treatment
entri
either
inhibitor
effect
control
cell
treat
inhibitor
infect
influenza
viru
infect
cell
fix
h
postinfect
detect
immunofluoresc
microscopi
antiinfluenza
nucleoprotein
monoclon
antibodi
fig
neither
cathepsin
b
cathepsin
l
inhibitor
effect
influenza
viru
entri
pretreat
cathepsin
k
inhibitor
effect
cellular
entri
either
influenza
viru
data
shown
data
show
imag
least
three
independ
experi
process
quantifi
b
control
nonspecif
effect
inhibitori
effect
cathepsin
inhibitor
manifest
viru
entri
lysosomotrop
agent
nh
cl
bafilomycin
well
establish
disrupt
acid
environ
endocyt
compart
assess
role
low
ph
entri
cell
pretreat
either
nh
cl
bafilomycin
first
assess
effect
nh
cl
weak
base
act
neutral
low
ph
endosom
pretreat
mm
nh
cl
partial
inhibit
entri
approxim
inhibit
howev
concentr
almost
complet
block
entri
fig
even
follow
pretreat
mm
nh
cl
entri
partial
block
compar
control
experi
use
influenza
viru
sendai
viru
influenza
viru
well
establish
requir
low
ph
trigger
fusion
mechan
complet
inhibit
pretreat
mm
nh
cl
analog
result
obtain
fig
sendai
viru
known
fuse
neutral
ph
accordingli
show
reduct
entri
cell
pretreat
nh
cl
fig
next
assess
effect
bafilomycin
inhibitor
vacuolartyp
h
atpas
pretreat
cell
nm
bafilomycin
complet
block
entri
influenza
viru
partial
block
entri
approxim
inhibit
sendai
viru
entri
unaffect
bafilomycin
concentr
test
treatment
entri
nh
cl
bafilomycin
minim
effect
concentr
shown
fig
howev
higher
concentr
nm
bafilomycin
mm
nh
cl
abl
significantli
reduc
infect
virus
data
shown
posttreat
bafilomycin
effect
influenza
sendai
viru
infect
concentr
shown
fig
overal
data
show
entri
highli
depend
low
endosom
ph
wherea
much
less
depend
low
ph
entri
determin
whether
effect
low
ph
cathepsin
inhibitor
gener
applic
serotyp
ii
coronaviru
infect
repeat
key
experi
use
addit
felin
coronaviru
strain
also
test
varieti
establish
felin
cell
line
crfk
akd
shown
fig
result
consist
previou
data
see
fig
cathepsin
b
inhibitor
almost
complet
prevent
infect
felin
coronavirus
test
wherea
cathepsin
l
inhibitor
zfi
tbu
dmk
select
inhibit
show
littl
effect
infect
likewis
weak
base
nh
cl
select
inhibit
cell
line
test
show
margin
effect
fipv
biotyp
investig
whether
effect
cathepsin
b
l
occur
level
spike
protein
cleavag
concentr
viral
particl
incub
purifi
activ
cathepsin
b
cathepsin
l
h
analyz
western
blot
antifcov
monoclon
antibodi
specif
protein
shown
fig
cathepsin
l
unabl
cleav
spike
protein
condit
test
clearli
abl
cleav
spike
protein
obviou
cleavag
product
approxim
kda
contrast
cathepsin
b
abl
cleav
spike
protein
also
produc
cleavag
product
replic
cell
also
treat
inhibitor
h
postinfect
quantif
cell
score
three
independ
replic
experiment
condit
error
bar
repres
standard
deviat
mean
fig
effect
lysosomotrop
agent
entri
cell
pretreat
nh
cl
bafilomycin
specifi
concentr
infect
viru
h
postinfect
cell
fix
stain
immunofluoresc
microscopi
antifcov
nucleocapsid
mab
imag
least
three
independ
experi
process
quantifi
b
control
nonspecif
effect
replic
cell
also
treat
lysomotroph
agent
h
postinfect
quantif
cell
score
three
independ
replic
experiment
condit
error
bar
repres
standard
deviat
mean
approxim
kda
fig
sampl
shown
fig
treat
endoglycosidas
pngase
f
result
clearer
represent
cleav
product
western
blot
compar
sampl
without
pngasef
pretreat
like
due
heterogen
glycosyl
spike
protein
sampl
without
glycosidas
data
shown
overal
data
indic
cathepsin
l
select
cleav
protein
wherea
cathepsin
b
cleav
protein
vivo
target
highli
virul
coronavirus
includ
felin
monocyt
macrophag
order
assess
whether
cathepsin
b
l
might
play
role
entri
vivo
target
isol
primari
felin
blood
monocyt
pretreat
cell
cathepsin
b
inhibitor
cathepsin
l
inhibitor
zfi
tbu
dmk
infect
shown
fig
cathepsin
b
inhibitor
significantli
reduc
infect
approxim
inhibit
howev
block
complet
observ
cell
line
see
fig
line
data
use
cell
line
cathepsin
l
inhibitor
show
signific
effect
fipv
infect
primari
felin
monocyt
expect
dewerchin
et
al
primari
felin
blood
monocyt
neglig
suscept
infect
henc
role
cathepsin
b
l
determin
case
fig
data
indic
cathepsin
bmediat
cleavag
may
play
import
role
cell
infect
vivo
cours
fip
show
effect
low
ph
cathepsin
cleavag
serotyp
ii
felin
coronaviru
spike
protein
differenti
effect
low
ph
cathepsin
b
versu
cathepsin
l
cleavag
fecv
fipv
biotyp
two
biotyp
genotyp
similar
strain
particular
known
share
high
degre
amino
acid
ident
spike
protein
yet
caus
radic
differ
clinic
outcomesleth
vascul
compar
mild
enter
haijema
et
al
previou
studi
shown
domain
viral
spike
protein
critic
discrimin
factor
pathogenesi
studi
present
rais
possibl
differenti
proteolysi
spike
protein
might
import
factor
explain
differ
pathogen
properti
virus
present
definit
determin
exact
point
fcov
infecti
cycl
cathepsin
cleavag
would
occur
howev
vivo
local
cathepsin
endosomelysosom
system
togeth
absenc
obviou
cleav
product
purifi
extracellular
fcov
particl
unless
exogen
activ
cathepsin
ad
would
strongli
suggest
cleavag
occur
endosom
viru
entri
support
find
addit
cathepsin
inhibitor
viru
entri
occur
detect
effect
viral
replic
use
felin
aminopeptidas
n
fapn
receptor
serotyp
ii
felin
coronavirus
well
establish
tresnan
et
al
tusel
et
al
van
hamm
et
al
mani
aspect
entri
pathway
explor
great
detail
virus
base
effect
lysosomotrop
agent
shown
suggest
serotyp
ii
felin
coronavirus
enter
endocyt
pathway
viru
entri
prime
fusion
activ
cathepsin
cleavag
much
depend
endosom
function
suggest
may
escap
cytosol
earlier
endocyt
pathway
possibl
might
account
differenti
cleavag
fipv
spike
protein
cathepsin
l
altern
lower
threshold
necessari
low
phdepend
conform
chang
fipv
spike
remain
determin
whether
similar
situat
cathepsin
cleavag
exist
serotyp
fcov
consid
share
receptor
dye
et
al
gener
cleavag
site
cathepsin
difficult
predict
base
sequenc
specif
present
determin
specif
spike
protein
cathepsin
b
l
might
cleav
howev
base
singl
kda
cleav
product
seen
fig
cathepsin
b
l
appear
spike
protein
subject
singl
distinct
cleavag
event
proteas
like
occur
approxim
posit
use
monoclon
antibodi
show
specif
cleavag
event
epitop
recogn
known
analog
mani
sspecif
fcov
monoclon
antibodi
epitop
corapi
et
al
olsen
et
al
tent
suggest
epitop
also
like
within
domain
base
cleavag
pattern
shown
fig
appear
cleavag
occur
boundari
rather
kda
cleavag
product
observ
may
repres
cleavag
within
ctermin
part
ctermin
part
fcov
previous
consid
specifi
pathogen
catli
mm
nh
cl
infect
viru
h
postinfect
cell
fix
stain
immunfluoresc
microscopi
antifcov
nucleocapsid
mab
imag
least
three
independ
experi
process
quantifi
quantif
cell
score
three
independ
replic
error
bar
repres
standard
deviat
mean
properti
fipv
interest
determin
specif
mutat
spike
account
differenti
cathepsinsensit
observ
interestingli
treatment
cathepsin
l
b
result
fraction
spike
protein
cleav
approxim
cleav
depend
cathepsinviru
combin
see
fig
may
indic
cleavag
site
rel
inaccess
small
number
spike
protein
cleav
viru
entri
regard
noteworthi
mani
case
cleavag
activ
viral
fusion
protein
necessarili
occur
copi
protein
exampl
see
michalski
et
al
data
also
indic
cleav
cathepsin
b
l
cleavag
occur
greater
degre
cathepsin
b
see
fig
data
consist
inhibitor
treatment
cathepsin
b
inhibitor
greater
effect
viru
infect
cathepsin
l
inhibitor
thu
consid
cathepsin
b
may
import
proteas
mediat
fcov
entri
cathepsin
l
possibl
secondari
role
cystein
proteas
cathepsin
b
l
k
emerg
therapeut
target
rang
diseas
includ
cancer
osteoarthr
autoimmun
disord
candid
drug
current
clinic
trial
turk
guncar
vasiljeva
et
al
cathepsin
inhibitor
also
show
promis
drug
target
viru
entri
vasiljeva
et
al
result
show
clear
role
cathepsin
b
entri
serotyp
ii
felin
coronavirus
rais
possibl
cathepsin
b
inhibitor
may
effect
therapeut
treat
incur
lethal
afflict
cat
fig
effect
cathepsin
inhibitor
infect
primari
felin
blood
monocyt
monocyt
purifi
blood
spf
cat
pretreat
cathepsin
b
inhibitor
catbi
cathepsin
l
inhibitor
zfi
tbu
dmk
catli
concentr
mm
infect
viru
h
postinfect
cell
fix
stain
immunofluoresc
microscopi
antifcov
nucleocapsid
mab
imag
least
three
independ
experi
process
quantifi
b
quantif
cell
score
three
independ
replic
experiment
condit
error
bar
repres
standard
deviat
mean
